Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Nat Biomed Eng. 2021 Nov 1;5(11):1320–1335. doi: 10.1038/s41551-021-00805-x

ED Fig. 4. Antitumour activity of BML-210 and CUDC-101 in mouse breast tumour models with CD4+ or CD8+ T-cell depletion.

ED Fig. 4

a, Drug-treatment scheme of mouse breast tumour models. b, Flow cytometry gating strategy for analysis of CD4+ and CD8+ T cells from EO771 tumours in C57BL/6 mice. c, Typical graphs showing the proportion of CD4+ and CD8+ T cells in total T cells (CD3+) from EO771 tumours treated with vehicle control or indicated compound, and with CD4 or CD8 depletion. d,e, Proportions of CD8+ (d) and CD4+ (e) T cells in total T cells from EO771 tumours with CD4 or CD8 depletion. f,g, Weight of the EO771 tumours from the tumour-bearing C57BL/6 mice treated with control, CUDC-101 (20 mg kg−1), BML-210 (20 mg kg−1), anti-CD8 (10 mg kg−1) + CUDC-101 (20 mg kg−1), anti-CD8 (10 mg kg−1) + BML-210 (20 mg kg−1), anti-CD4 (10 mg kg−1) + CUDC-101 (20 mg kg−1) or anti-CD4 (10 mg kg−1) + BML-210 (20 mg kg−1). Tumours from tumour-bearing C57BL/6 mice were harvested at day 28 post injection. For statistical analysis of data, two-way ANOVA test was used in (d,e). One-way ANOVA test was used in (f,g). Data are presented as mean ± SD. ****, p < 0.0001; ns, no significance.